Among transfusion-related complications, the Hemosiderosis is an incident characterized by a very low level of reporting. We have analyzed Hemosiderosis at national state and inside our CCAA (regions). Post-transfusion hemosiderosis is a frequent complication of hematologic diseases, as well as part of their treatment. It is defined as the accumulation of iron in organs and tissues in patients who are receiving regular transfusions of packed red blood cells.

In patients with anemia and ineffective erythropoiesis, an increase in intestinal iron absorption is produced due to low levels of hepcidin. This iron overload is more serious when these patients require continuous blood transfusions. On the other hand, malignant hematological diseases will require regularly transfusions, either as part of the treatment of the disease itself or as a result of the anemia-inducing effect caused by the anti neoplastic treatment. Iron overload, therefore, will be a common side effect in these patients. It is directly related to the number of transfusions received. A red cell concentrate contains from 200 to 250mg of iron. After transfusing 10 bags of red blood cells, iron is deposited in tissues, where it can produce toxicity. After 20 packed red blood cells, the risk of developing a secondary hemochromatosis increases.

We intend to investigate the percentage of hemosiderosis reports to the Spanish Haemovigilance system. In the European Union, there are various HV systems, to note French Haemovigilance system: It is governmental, with a complex structure, notification of all adverse effects and mandatory reporting. English Haemovigilance system (SHOT): Financed by scientific societies and professional associations, with simpler structure, notification of serious adverse effects and voluntary reporting. Spanish system (HV): a simpler structure model, with voluntary reporting of adverse events and reactions. Notifications are virtually nonexistent, except in the French system. Although reporting of post-transfusion hemosiderosis is mandatory in the French hemovigilance network since 1994, existing data is limited.

Patients, materials and methods
We reviewed the transfusion incidents caused by iron overload which have been reported to the Spanish HV system and the Andalusia HV system, comparing them with the ones notified by our hospital from 2013 to 2016 and their underlying hematologic diseases.

Notifications to the spanish HV system were
i. 2007:3 cases.
ii. 2008:15 cases.
iii. 2009:10 cases.
iv. 2010:10 cases.
v. 2011:16 cases.
vi. 2012:10 cases.
vii. 2013:88 cases.
viii. 2014:108 cases.
ix. 2015:69 cases.

Notifications to the autonomous community of andalusia were
i. 2007-2012: 0 cases.
ii. 2013:71 cases.
iii. 2014:90 cases.
v. 2015:Results have not been published yet.

Results
In 2013, we identified 57 cases, 32 men and 25 women, from...
20 to 87 years old, with an average of 56 years old, who have been transfused with packed red blood cells. The results vary from 10 CH to 73 CH transfused (average of 25 CH per patient). Post transfusional ferritin levels in all patients were over 1000 ng/ml with an average of 2869 ng/ml. In 2014 we have notified 76 cases to the HV system, from 24 to 83 years old, 50 men and 26 women (average of 56 years old). The number of CH transfused varied from 10 to 130 (average of 31 CH). The number of post-transfusion ferritin ranged between 1,041 and 15,190 ng/ml.

In 2015, 42 cases have been reported: 18 women and 24 men, between the ages of 17 and 81, with an average of 51 years old. The number of CH transfused ranged from 10 to 107 (average of 33.3 CH). Post-transfusion ferritin ranged between 1.274 and 8.858 ng/ml. In 2016, 41 cases have been reported: 30 men and 11 women, between the ages of 6 and 92, with an average of 57 years old. The number of CH transfused ranged from 10 to 71 (average of 36.48 CH). Post-transfusion ferritin ranged between 1.027 and 35.063 ng/ml (Table 1).

Firstly, the largest number of hyperferritinemia cases was found in patients with acute myeloid leukemia. Secondly, in patients with monoclonal gammopathies and thirdly in patients with non-Hodgkin lymphoma. Other diagnoses were myelodysplastic syndrome, chronic lymphocytic leukemia etc.

Table 1 Post transfusional ferritin levels in all patients

<table>
<thead>
<tr>
<th>Years</th>
<th>Men</th>
<th>Women</th>
<th>Median age</th>
<th>Median CH</th>
<th>Median ferritin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>32</td>
<td>25</td>
<td>56</td>
<td>25</td>
<td>2.869 ng/ml</td>
</tr>
<tr>
<td>2014</td>
<td>50</td>
<td>26</td>
<td>56</td>
<td>31</td>
<td>3.238 ng/ml</td>
</tr>
<tr>
<td>2015</td>
<td>18</td>
<td>24</td>
<td>51</td>
<td>33</td>
<td>3.457 ng/ml</td>
</tr>
<tr>
<td>2016</td>
<td>30</td>
<td>11</td>
<td>57</td>
<td>36</td>
<td>6.961 ng/ml</td>
</tr>
</tbody>
</table>

In Figure 1, other diagnoses were myelodysplastic syndrome, chronic lymphocytic leukemia etc.

### Conclusion

The most frequent cause of hemosiderosis secondary to transfusion in our hospital has been acute leukemia, with a predominance of acute myeloid leukemia over acute lymphoblastic leukemia. It is very important to properly track ferritin levels in patients who are undergoing multiple transfusions, in order to establish chelation therapy when necessary and to prevent the organic damage of secondary hemochromatosis. Looking at the results published by the Andalusian HV system in 2013 and 2014, we can highlight the increase of notifications of post-transfusion hemosiderosis to the hemovigilance system, as well as the increasing number of near-miss reported in 2013. This is valued as an improvement in the notification of such events. Communication of Hemosiderosis cases to the hemovigilance System helps to create protocols for poly transfused patients because of hematologic diseases. Hemovigilance in Spain is, today, a fully integrated tool within the activities carried out by Transfusion Hospital Centers and Services. Among the remaining challenges, we highlight: Getting a more uniform level of notification and moving forward in the optimal use of blood and blood components: safe, effective and efficient.

### Acknowledgements

None.

### Conflict of interest

The author declares no conflict of interest.

### References


---